CA3025473A1 - Methods of treating behavioral syndromes using pipradrol - Google Patents
Methods of treating behavioral syndromes using pipradrol Download PDFInfo
- Publication number
- CA3025473A1 CA3025473A1 CA3025473A CA3025473A CA3025473A1 CA 3025473 A1 CA3025473 A1 CA 3025473A1 CA 3025473 A CA3025473 A CA 3025473A CA 3025473 A CA3025473 A CA 3025473A CA 3025473 A1 CA3025473 A1 CA 3025473A1
- Authority
- CA
- Canada
- Prior art keywords
- pipradrol
- methods
- pharmaceutically acceptable
- disorder
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960000753 pipradrol Drugs 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 59
- XSWHNYGMWWVAIE-UHFFFAOYSA-N pipradrol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1CCCCN1 XSWHNYGMWWVAIE-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 230000003542 behavioural effect Effects 0.000 title claims abstract description 31
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 26
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 19
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract description 19
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 39
- 208000024891 symptom Diseases 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 24
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 12
- 229950004346 gaboxadol Drugs 0.000 claims description 12
- 208000013403 hyperactivity Diseases 0.000 claims description 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 2
- 229960000571 acetazolamide Drugs 0.000 claims description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001403 clobazam Drugs 0.000 claims description 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 2
- 229960003120 clonazepam Drugs 0.000 claims description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 2
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 claims description 2
- 229960003233 eslicarbazepine acetate Drugs 0.000 claims description 2
- 229960002767 ethosuximide Drugs 0.000 claims description 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 2
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- 229960002623 lacosamide Drugs 0.000 claims description 2
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims description 2
- 229960001848 lamotrigine Drugs 0.000 claims description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 2
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 claims description 2
- 229960001454 nitrazepam Drugs 0.000 claims description 2
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001816 oxcarbazepine Drugs 0.000 claims description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960005198 perampanel Drugs 0.000 claims description 2
- PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002695 phenobarbital Drugs 0.000 claims description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002036 phenytoin Drugs 0.000 claims description 2
- 229960004526 piracetam Drugs 0.000 claims description 2
- 229960001233 pregabalin Drugs 0.000 claims description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 2
- 229960002393 primidone Drugs 0.000 claims description 2
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003312 retigabine Drugs 0.000 claims description 2
- 229960003014 rufinamide Drugs 0.000 claims description 2
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 2
- 229940084026 sodium valproate Drugs 0.000 claims description 2
- 229960001897 stiripentol Drugs 0.000 claims description 2
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 claims description 2
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 2
- 229960001918 tiagabine Drugs 0.000 claims description 2
- 229960004394 topiramate Drugs 0.000 claims description 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 2
- 229960005318 vigabatrin Drugs 0.000 claims description 2
- 229960002911 zonisamide Drugs 0.000 claims description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 201000010099 disease Diseases 0.000 description 20
- 229910052805 deuterium Inorganic materials 0.000 description 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 206010010904 Convulsion Diseases 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- -1 pipradrol Chemical class 0.000 description 5
- 239000000021 stimulant Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 201000003631 narcolepsy Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000025480 CHILD syndrome Diseases 0.000 description 3
- 208000028603 Interstitial lung disease specific to childhood Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001660 hyperkinetic effect Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010054196 Affect lability Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010013486 Distractibility Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000011262 co‐therapy Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- OXOBKZZXZVFOBB-UHFFFAOYSA-N 2-diphenylmethylpyrrolidine Chemical compound C1CCNC1C(C=1C=CC=CC=1)C1=CC=CC=C1 OXOBKZZXZVFOBB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 206010022035 Initial insomnia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000000688 desorption electrospray ionisation Methods 0.000 description 1
- RWTNXJXZVGHMGI-UHFFFAOYSA-N desoxypipradrol Chemical compound N1CCCCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 RWTNXJXZVGHMGI-UHFFFAOYSA-N 0.000 description 1
- OGCGXUGBDJGFFY-UHFFFAOYSA-N diphenylprolinol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1CCCN1 OGCGXUGBDJGFFY-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002825 dopamine reuptake Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000024196 oppositional defiant disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 208000021011 postpartum psychosis Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000216 proconvulsive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341855P | 2016-05-26 | 2016-05-26 | |
| US62/341,855 | 2016-05-26 | ||
| PCT/US2017/034443 WO2017205606A1 (en) | 2016-05-26 | 2017-05-25 | Methods of treating behavioral syndromes using pipradrol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3025473A1 true CA3025473A1 (en) | 2017-11-30 |
Family
ID=60408578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3025473A Abandoned CA3025473A1 (en) | 2016-05-26 | 2017-05-25 | Methods of treating behavioral syndromes using pipradrol |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9827233B1 (enExample) |
| EP (1) | EP3439657A4 (enExample) |
| JP (1) | JP2019517469A (enExample) |
| KR (1) | KR20190013737A (enExample) |
| CN (1) | CN109414435A (enExample) |
| AU (1) | AU2017268795A1 (enExample) |
| CA (1) | CA3025473A1 (enExample) |
| IL (1) | IL262986A (enExample) |
| MX (1) | MX2018013973A (enExample) |
| WO (1) | WO2017205606A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391708B (es) | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| US9351968B1 (en) * | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| JP2019517469A (ja) * | 2016-05-26 | 2019-06-24 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ピプラドロールを用いる行動症候群の治療方法 |
| US20190076409A1 (en) * | 2017-09-12 | 2019-03-14 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of narcolepsy |
| KR20210062662A (ko) | 2018-09-20 | 2021-05-31 | 오비드 테라퓨틱스 인크. | 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용 |
| AU2019384157A1 (en) | 2018-11-21 | 2021-06-17 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| KR20210105387A (ko) | 2018-12-17 | 2021-08-26 | 오비드 테라퓨틱스 인크. | 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용 |
| GB201911056D0 (en) * | 2019-08-02 | 2019-09-18 | Sanchez Hector Mario | Treatment of ADD/ADHD |
| KR20230028244A (ko) | 2020-05-20 | 2023-02-28 | 썰테고 테라퓨틱스 아이엔씨. | 고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830083A (en) | 1953-04-29 | 1958-04-08 | Allied Chem & Dye Corp | Production of aryloxy aliphatic carboxylic acids |
| US3947579A (en) | 1974-06-03 | 1976-03-30 | Nelson Research & Development Company | Method and composition for potentiating neuroleptic drugs |
| US4084000A (en) | 1975-07-16 | 1978-04-11 | Nelson Research And Development Company | Method of treating schizophrenia |
| US4129652A (en) | 1976-08-16 | 1978-12-12 | Nelson Research & Development Company | Method for potentiating neuroleptic drugs |
| US5650521A (en) * | 1995-12-29 | 1997-07-22 | Guilford Pharmaceuticals Inc. | Pyrrolidine derivatives |
| WO2008095221A1 (en) * | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| CN102123586A (zh) | 2008-07-18 | 2011-07-13 | 法弗根股份有限公司 | 治疗超重或肥胖受试者的方法 |
| FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| US20100260844A1 (en) * | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| US20120302590A1 (en) * | 2009-08-13 | 2012-11-29 | The General Hospital Corporation | Methods and compositions to prevent addiction |
| EP2575853B1 (en) | 2010-05-25 | 2016-08-24 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient |
| US9028868B2 (en) * | 2011-03-23 | 2015-05-12 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| JP2019517469A (ja) * | 2016-05-26 | 2019-06-24 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ピプラドロールを用いる行動症候群の治療方法 |
-
2017
- 2017-05-25 JP JP2018561714A patent/JP2019517469A/ja active Pending
- 2017-05-25 CN CN201780032282.5A patent/CN109414435A/zh active Pending
- 2017-05-25 US US15/604,776 patent/US9827233B1/en active Active
- 2017-05-25 CA CA3025473A patent/CA3025473A1/en not_active Abandoned
- 2017-05-25 MX MX2018013973A patent/MX2018013973A/es unknown
- 2017-05-25 KR KR1020187032669A patent/KR20190013737A/ko not_active Ceased
- 2017-05-25 AU AU2017268795A patent/AU2017268795A1/en not_active Abandoned
- 2017-05-25 WO PCT/US2017/034443 patent/WO2017205606A1/en not_active Ceased
- 2017-05-25 EP EP17803569.7A patent/EP3439657A4/en not_active Withdrawn
- 2017-10-19 US US15/788,168 patent/US20180036298A1/en not_active Abandoned
-
2018
- 2018-11-08 US US16/183,933 patent/US10493069B2/en active Active
- 2018-11-13 IL IL262986A patent/IL262986A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019517469A (ja) | 2019-06-24 |
| CN109414435A (zh) | 2019-03-01 |
| AU2017268795A1 (en) | 2018-11-22 |
| MX2018013973A (es) | 2019-03-28 |
| US20170340619A1 (en) | 2017-11-30 |
| EP3439657A4 (en) | 2019-12-18 |
| US20180036298A1 (en) | 2018-02-08 |
| KR20190013737A (ko) | 2019-02-11 |
| IL262986A (en) | 2018-12-31 |
| US9827233B1 (en) | 2017-11-28 |
| EP3439657A1 (en) | 2019-02-13 |
| WO2017205606A1 (en) | 2017-11-30 |
| US10493069B2 (en) | 2019-12-03 |
| US20190076415A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10493069B2 (en) | Methods of treating behavioral syndromes using pipradrol | |
| US9913833B2 (en) | Methods of treating developmental disorders using pipradrol | |
| US9682069B2 (en) | Methods of treating Dravet syndrome | |
| US5854290A (en) | Use of guanfacine in the treatment of behavioral disorders | |
| JP6119068B2 (ja) | 認知障害の処置に有用なα−アミノアミド誘導体 | |
| US20190328719A1 (en) | Methods of treating developmental disorders and/or seizure disorders with flupirtine | |
| GARA et al. | Adverse response to methylphenidate in combination with valproic acid | |
| US20120046302A1 (en) | Methods of treating cns disorders | |
| WO2010126527A1 (en) | Methods of treating cns disorders | |
| US5863934A (en) | Use of lofexidine in the treatment of behavioral disorders | |
| EP3897578B1 (en) | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders | |
| US10765666B2 (en) | Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering | |
| JP2023549134A (ja) | Ｔ型カルシウムチャネル調節因子及びその使用方法 | |
| HK40063144A (en) | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230822 |